Catalyst Pharmaceuticals, Inc.
CPRX
$21.34
$0.221.04%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 1.43% | 27.46% | 7.57% | 75.27% | -33.20% |
| Total Depreciation and Amortization | 0.02% | 0.07% | 0.17% | 0.05% | 3.14% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -13.42% | 114.95% | -231.79% | -33.14% | 96.33% |
| Change in Net Operating Assets | -258.56% | -83.20% | 206.13% | 199.99% | -212.97% |
| Cash from Operations | -15.29% | -2.74% | 13.62% | 100.89% | -42.63% |
| Capital Expenditure | -- | 66.02% | -2,490.00% | 94.97% | 99.45% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 66.02% | -2,490.00% | 94.97% | 99.48% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -20.00% | 50.43% | 95.86% | -98.57% | 20,465.95% |
| Repurchase of Common Stock | -38.36% | -- | -- | 100.00% | 54.97% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.18% | 89.08% | -1,038.67% | 31.13% | -40.22% |
| Cash from Financing | -30.97% | 174.20% | -616.34% | -99.18% | 21,310.38% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -16.11% | 12.88% | 2.08% | -62.22% | 936.75% |